Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

ären Endpunktes zuzüglich Hospitalisierung infolge instabiler Angina Pectoris, die eine koronare Revaskularisierung innerhalb von 24 Stunden nach Einweisung erforderte. Eine Prüfung des sekundären kombinierten Endpunkts zeigte bei Alogliptin und Placebo keine Unterschiede (12,7 % bzw. 13,4 %; Risikoverhältnis 0,95; obere Grenze des Konfidenzintervalls ( KI) 1,14).

Andere sekundäre Endpunkte waren alle kardiovaskulären Todesfälle und Gesamtmortalität (alle Todesfälle, gleich welcher Ursache). Der KV-Tod trat bei 112 mit Alogliptin behandelten Patienten (4,1 %) und 130 mit Placebo behandelten Patienten (4,9 %) bei einem Risikoverhältnis von 0,85 ein (95 % Konfidenzintervall von 0,66 bis 1,10, p=0,21). Insgesamt verstarben 153 der mit Alogliptin behandelten Patienten (5,7%) und 173 der mit Placebo behandelten Patienten (6,5%) bei einem Risikoverhältnis von 0,88 ein (95 % Konfidenzintervall von 0,71 bis 1,09, p=0,23). Das zeigt, dass die Ereignisraten sich statistisch nicht voneinander unterschieden. Darüber hinaus wurden das Auftreten von Angioödemen, Hypoglykämien, Pankreatitiden, Tumorerkrankungen sowie Laborergebnisse untersucht. Die Anzahl von Hypoglykämien,  verschiedenen Tumorerkrankungen, Pankreatitiden, Fällen von Dialysepflichtigkeit und erhöhten Serum-Aminotransferasewerten waren bei der Alogliptin- und der Placebogruppe ähnlich. Während der Studie wurde kein Fall von Pankreaskarzinom berichtet. Die Alogliptin- und die Placebogruppe wichen hinsichtlich des Anteils schwerwiegender unerwünschter Ereignisse nicht signifikant voneinander ab (33,6 % bzw. 35,5 %, p=0,14).

Informationen zu EXAMINE
EXAMINE war eine globale randomisierte, Placebo kontrollierte klinische Doppelblindstudie. Ihr Ziel war die Bewertung der kardiovaskulären Sicherheit der Behandlung mit Alogliptin zusätzlich zur Standardthe
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... LAUSANNE , Switzerland , October ... European leader in Clinical Genomics and Next Generation Sequencing ... Solution allowing clinicians to run full cystic fibrosis analysis ... covers the identification and characterisation of all types of ... analytical performance. Until now, it has not ...
(Date:9/30/2014)...  Wrightington, Wigan and Leigh ... MDRX ) are delighted to announce WWL,s decision to ... information system. The system will be implemented across all ... WWL delivers healthcare in the future. ... on-time and on-budget system implementations as well as its ...
(Date:9/30/2014)... , Sept. 30, 2014  Tasly Pharmaceuticals, ... to modernize medicine, announced today the launch of ... nutraceuticals developed to address men and women concerned ... and vibrant into old age while helping keep ... three condition-specific, whole-food and herb-based formulas, namely, ProHeart ...
Breaking Medicine Technology:Sophia Genetics Launches Full CFTR Analysis in Single Clinical Grade NGS Experiment 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 2Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 3Wrightington, Wigan and Leigh NHS Foundation Trust selects Allscripts Sunrise 4
... Cosmetic dentist in Los Angeles , Dr. Kevin ... oral health of superstars and celebrities around the world. Celebrities ... dental practice of Dr. Sands delivers every time. Dr. Sands ... all patients receive VIP treatment upon arrival for general and ...
... 2011 Cornerstone Pharmaceuticals, Inc., a leader in ... a preclinical toxicity study of azide drug-loaded Emulsiphan ... (NCI) under a Collaboration Agreement. Emulsiphan is Cornerstone,s ... are so pleased that Cornerstone has received a ...
Cached Medicine Technology:Los Angeles Dentist, Dr. Kevin Sands, Uses the Latest Technologies to Provide VIP Services and Treatments for His Patients 2Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study 2Cornerstone Pharmaceuticals Announces Positive Results of Emulsiphan Safety Study 3
(Date:10/1/2014)... Patients with increased inflammation, including those receiving cytokines ... of depression. For example, a 6-month treatment course ... infection causes depression in approximately 30% of patients. ... as fish oil, have a long list of ... disease and reducing triglyceride levels. These nutritional compounds ...
(Date:10/1/2014)... 01, 2014 Familylifeinsurancequotes.org has released ... insurance for senior citizens. , Senior citizens can ... now sell coverage to seniors who are over 50 ... purchased without taking a medical examination. , Term life ... and senior clients can qualify. Having life insurance during ...
(Date:10/1/2014)... CA (PRWEB) October 01, 2014 Bedros ... Fit Body Boot Camp fitness boot camps, he’s also ... personal training , with sold out business summits, a ... as marketing consultant to a recent Spike TV reality ... says that now is the time for personal trainers ...
(Date:10/1/2014)... Phoseon Technology, the pioneer in developing ... business worldwide. This rapid growth includes increased hiring for ... efforts. The company has experienced average annual growth rates ... this growth to continue in the future as new ... , “We are very pleased that UV ...
(Date:10/1/2014)... Join the more than 80 golfers who already ... ever charity golf tournament to benefit Project HEAL, a not-for-profit ... cannot afford treatment. The tournament will be held Monday, Oct. ... , The day-long event starts with 10:30 a.m. check-in and ... will begin at 5 p.m. and will include an auction ...
Breaking Medicine News(10 mins):Health News:Omega-3 fatty acids may prevent some forms of depression 2Health News:Affordable Term Life Insurance - Senior Citizens Can Qualify for Coverage! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:Phoseon Technology Continues to Drive Growth Worldwide 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... Southwestern Medical Center, working with mice, have shown how ... decrease the fearful response associated with reliving a traumatic ... a mild electrical shock – mice in the study ... place where it happened, a condition that could be ...
... has claimed five more victims in Bataan, Rizal and ... child from Valenzuela City and a four-and-a-half child from ... Lustre, administrator of the Amang Rodriguez Medical Center the ... 10 hours after being taken there for treatment Wednesday. ...
... out for carbohydrate molecules so as to prepare for an ... the University of Florida, which has been published in the ... humans but viruses too that crave for carbohydrates. The researchers ... that overhang from the surface of our cells and stage ...
... Scientists claimed to have developed a blood test for ... the St George's Hospital and the Medical Research Council ... the test is 94% accurate. They further explained that ... infection. ,The current technique that is used ...
... clinic, injecting an anesthetic at certain points can reduce the ... is being presented today at the annual meeting of the ... Diego, had found that about 16% of patients encounter a ... was explained that the biopsies are commonly performed on men ...
... of Texas, Ann Richards marks the rapid increase in esophageal cancer ... diagnosed with esophageal cancer.// Only 16 % or around 2,200, of ... survive in 5 years. ,There has been a 6-fold annual ... 20 years, according to experts. Rise in obesity cases has been ...
Cached Medicine News:Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 2Health News:Pre-Clinical Study Suggests How Steroid Can Reverse Post-Traumatic Stress 3Health News:Virus Can Mutate lethally With Help Of Carbohydrates 2Health News:Virus Can Mutate lethally With Help Of Carbohydrates 3Health News:Rise in Esophageal Cancer is emphasized by Richards’ deat 2
... over a wide range of concentration, ... more thorough characterization than other methods. ... relative change in the distribution of ... to measure heterogeneity, stoichiometry and self-associating ...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Alkaline phosphatase FS (DGKC new; 37C). For determination of alkaline phosphatase (ALP) in serum or plasma. For Hitachi 717. Controls: Trulab N and Trulab P....
For the quantitative determination of alkaline phosphatase in human serum....
Medicine Products: